Journal Mobile Options
Table of Contents
Vol. 23, No. 2, 2007
Issue release date: January 2007

Differential CSF Biomarker Levels in APOE-ε4-Positive and -Negative Patients with Memory Impairment

Andersson C. · Blennow K. · Johansson S.-E. · Almkvist O. · Engfeldt P. · Lindau M. · Eriksdotter-Jönhagen M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: To investigate the relationships between episodic memory, APOE genotype, CSF markers (total tau, T-tau; phospho-tau, P-tau; β-amyloid, Aβ42) and longitudinal cognitive decline. Methods: 124 memory clinic patients were retrospectively divided into 6 groups based on (i) episodic memory function (Rey Auditory Verbal Learning Test, RAVLT): severe, moderate or no impairment (SIM, MIM or NIM), and (ii) APOE genotype (ε4+ or ε4–). CSF marker levels and cognitive decline were compared across groups. Results: Episodic memory function, according to RAVLT scores, was significantly correlated with CSF marker levels only among ε4+ subjects and not among ε4– subjects. When comparing the 6 subgroups, SIM ε4+ and MIM ε4+ groups showed significantly lower Aβ42 levels than the other groups. T-tau and P-tau levels were significantly increased in SIM ε4+ when compared to all the other groups, including the SIM ε4– group. However, both SIM ε4+ and SIM ε4– declined cognitively during the follow-up. Conclusion: It remains to be determined whether APOE genotype affects the expression of biomarkers in CSF, or whether the different biomarker patterns reflect different types of disease processes in patients with progressive cognitive dysfunction.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Tierney M, Szalai JP, Snow WG, et al: Prediction of probable Alzheimer’s disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996;46:661–665.
  2. Almkvist O, Basun H, Bäckman L, et al: Mild cognitive impairment – An early stage of Alzheimer’s disease? J Neural Transm 1998;54(suppl):21–29.
  3. Petersen R, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment. Arch Neurol 1999;56:303–308.
  4. Arnàiz E, Almkvist O: Neuropsychological features of mild cognitive impairment and preclinical Alzheimer’s disease. Acta Neurol Scand 2003;179(suppl):34–41.

    External Resources

  5. Andersson C, Lindau M, Almkvist O, Engfeldt P, Johansson SE, Eriksdotter-Jönhagen M: Identifying patients at high and low risk for cognitive decline using Rey Auditory Verbal Learning Test among middle-aged memory clinic out-patients. Dement Geriatr Cogn Disord 2006;21:251–259.
  6. Tierney MC, Black SE, Szalai JP, et al: Recognition memory and verbal fluency differentiate probable Alzheimer’s disease from subcortical ischemic vascular dementia. Arch Neurol 2001;58:1654–1659.
  7. Traykov L, Baudic S, Thibaudet MC, Rigaud AS, Smagghe A, Boller F: Neuropsychological deficit in early subcortical dementia: comparison to Alzheimer’s disease. Dement Geriatr Cogn Disord 2002;14:26–32.
  8. Looi JC, Sachdev PS: Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999;53:670–678.
  9. Jones S, Jonsson Laukka E, Small BJ, Fratiglioni L, Bäckman L: A preclinical phase in vascular dementia: cognitive impairment three years before diagnosis. Dement Geriatr Cogn Disord 2004;18:233–239.
  10. Laukka EJ, Jones S, Small BJ, Fratiglioni L, Bäckman L: Similar patterns of cognitive deficits in the preclinical phases of vascular dementia and Alzheimer’s disease. J Int Neuropsychol Soc 2004;10:382–391.
  11. Blennow K: CSF biomarkers for mild cognitive impairment. J Intern Med 2004;256:224–234.
  12. Andreasen N, Minthon L, Davidsson P, et al: Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373–379.
  13. Sunderland T, Linker G, Mirza N, et al: Decreased β-amyloid 1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094–2103.
  14. Galasko D, Chang L, Clark CM, et al: High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937–945.
  15. Hsiung GR, Sadovnick D, Feldman H: Apolipoprotein E ε4 genotype as a genetic risk factor for cognitive decline and dementia: data from the Canadian study of health and aging. CMAJ 2004;171:863–867.
  16. Tsuang DW, Wilson RK, Lopez OL, et al: Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease. Neurology 2005;64:509–513.
  17. Lasser RA, Dukoff R, Levy J, et al: Apolipoprotein E ε4 allele in association with global cognitive performance and CSF markers and Alzheimer’s disease. Int J Geriatr Psychiatry 1998;13:767–774.
  18. Ganzer S, Arlt S, Schoder V, et al: CSF-tau, CSF-Aβ1–42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer’s disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity. J Neural Transm 2003;110:1149–1160.
  19. Tapiola T, Pirttilä T, Mehta P, Alafuzoff I, Lehtovirta M, Soininen H: Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease. Neurobiol Aging 2000;21:735–740.
  20. Golombowski S, Müller-Spahn F, Romig H, Mendla K, Hock C: Dependence of cerebrospinal fluid tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer’s disease. Neurosci Lett 1997;225:213–215.
  21. Riemenschneider M, Schmolke M, Lautenschlager N, et al: Cerebrospinal beta-amyloid (1–42) in early Alzheimer’s disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett 2000;284:85–88.
  22. Sunderland T, Mirza N, Putnam KT, et al: Cerebrospinal fluid β-amyloid 1–42 and tau in control subjects at risk for Alzheimer’s disease: the effect of ApoE ε4 allele. Biol Psychiatry 2004;56:670–676.
  23. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K: APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42. Neurology 2004;62:2116–2118.
  24. Ivaniou A, Sindic C: Cerebrospinal fluid tau protein and amyloid β42 in mild cognitive impairment: prediction of progression to Alzheimer’s disease and correlation with the neuropsychological examination. Neurocase 2005;11:32–39.

    External Resources

  25. Schoonenboom SNM, Visser PJ, Mulder C, et al: Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase 2005;11:8–13.
  26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–944.
  27. Blennow K, Vanmechelen E: CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull 2003;61:235–242.
  28. Visser PJ, Scheltens P, Verhey FRJ: Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer’s disease? J Neurol Neurosurg Psychiatry 2005;76:1348–1354.
  29. Schmidt M: Rey Auditory Verbal Learning Test – A Handbook. Los Angeles, Western Psychological Services, 1996.
  30. Folstein M, Folstein S, McHugh P: Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  31. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4 (DSM IV). Washington, American Psychiatric Association, 1994.
  32. Bartfai A, Nyman H, Stegman B: Wechsler adult intelligence scale revised. WAIS-R Manual. Stockholm, Psykologiförlaget, 1994.
  33. Andersson E, Berg S, Lawenius M, Svanborg A: Intellectual functioning in a 70-year-old urban population. Acta Psychiatr Scand 1978;57:59–66.
  34. Reitan R, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, Neuropsychology Press, 1993.
  35. Fernaeus SE, Almkvist O: Word production: dissociation of two retrieval modes of semantic memory across time. J Clin Exp Neuropsychol 1998;20:137–143.
  36. Lezak M: Neuropsychological Assessment, ed 3. New York, Oxford University Press, 1995.
  37. Wechsler D: Wechsler Memory Scale – Revised. New York, Psychological Corporation, 1987.
  38. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer’s disease? Mol Chem Neuropathol 1995;26:231–245.
  39. Vanmechelen E, Vanderstichele H, Davidsson P, et al: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49–52.
  40. Andreasen N, Hesse C, Davidsson P, et al: Cerebrospinal fluid C-amyloid(1–42) in Alzheimer’s disease: differences between early- and late-onset AD and stability during the course of disease. Arch Neurol 1999;56:673–680.
  41. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhAI. J Lipid Res 1990;31:545–548.
  42. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
  43. Guillozet A, Weintraub S, Mash D, Mesulam M: Neurofibrillary tangles, amyloid and memory in aging and mild cognitive impairment. Arch Neurol 2003;60:729–736.
  44. Traykov L, Baudic S, Raoux N, et al: Patterns of memory impairment and perseverative behavior discriminate early Alzheimer’s disease from subcortical vascular dementia. J Neurol Sci 2005;229–230:75–79.
  45. Wahlund LO, Pihlstrand E, Eriksdotter-Jönhagen M: Mild cognitive impairment: experience from a memory clinic. Acta Neurol Scand 2003;107(suppl 179):21–24.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50